biostudies-literatureMa XNational Natural Science Foundation Youth Fund1755416https://www.ebi.ac.uk/biostudies/studies/S-EPMC9427322biostudies-literatureUnknown2022<h4>Objectives</h4>Following cerebral ischemia, microRNA- (miR-) 29b in circulating blood is downregulated. This study investigates the underlying mechanism and implications of miR-29b in leukocyte induction.<h4>Methods</h4>miR-29b from stroke patients and rats with middle cerebral artery occlusion (MCAO) were assessed using real-time polymerase chain reaction (PCR). miR-29b agomir was used to increase miR-29b expression in leukocytes via intravenous injection. C1q and tumor necrosis factor (C1QTNF) 6, interleukin- (IL-) 1<i>β</i>, zonula occludens- (ZO-) 1, occludin, and ischemic outcomes were assessed in MCAO rats. Additionally, hCMEC/D3 cells were subjected to oxygen-glucose deprivation (OGD) and cocultured with HL-60 cells.<h4>Results</h4>miR-29b levels in neutrophils were found to be Mediators of inflammationMicroRNA-29b Suppresses Inflammation and Protects Blood-Brain Barrier Integrity in Ischemic Stroke.PMC942732281901194Li GYun HJDing YGuo YMa XElkin KfalseMicroRNA-29b Suppresses Inflammation and Protects Blood-Brain Barrier Integrity in Ischemic Stroke.<h4>Objectives</h4>Following cerebral ischemia, microRNA- (miR-) 29b in circulating blood is downregulated. This study investigates the underlying mechanism and implications of miR-29b in leukocyte induction.<h4>Methods</h4>miR-29b from stroke patients and rats with middle cerebral artery occlusion (MCAO) were assessed using real-time polymerase chain reaction (PCR). miR-29b agomir was used to increase miR-29b expression in leukocytes via intravenous injection. C1q and tumor necrosis factor (C1QTNF) 6, interleukin- (IL-) 1<i>β</i>, zonula occludens- (ZO-) 1, occludin, and ischemic outcomes were assessed in MCAO rats. Additionally, hCMEC/D3 cells were subjected to oxygen-glucose deprivation (OGD) and cocultured with HL-60 cells.<h4>Results</h4>miR-29b levels in neutrophils were found to be 2022-01-01T00:00:00Z20222025-04-05T00:42:31.878Z2025-02-19T03:28:51.777ZS-EPMC94273223605230710.1155/2022/1755416